ARDX (Ardelyx) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 02, 2026)


ARDX Ardelyx Inc ARDX
75 GF Score
Price $5.27
GF Value $10.20
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ardelyx Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Ardelyx's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

ARDX vs AVLN, INBX, JBIO: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Ardelyx's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ardelyx Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ardelyx's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Ardelyx's Margin of Safety % (DCF Earnings Based) falls into.


ARDX
75GF Score
Ardelyx Inc ARDX
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ardelyx (ARDX) Overvalued in 2026?

Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued. The current stock price of $5.27 is trading 48.3% below its estimated GF Value™ of $10.20. GuruFocus considers Ardelyx to be Possible Value Trap.

Key valuation signals for ARDX:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $10.20 vs. price of $5.27 (48.3% below fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ardelyx Business Description

Other Exchanges ARDX:Mexico41X:Germany
Address 400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
75GF Score

Get the complete analysis for ARDX

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.27
Price
$10.20
GF Value